This paper discusses about the incidence of basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (CSCC) surpasses that of all other cancers combined.Complete surgical excision with margin control remains the preferred treatment for BCC, resulting in cure rates of up to 98.6%.Nonetheless, surgery has limitations, particularly in the head and face, where disfiguration is a potential concern.Although alternative topical therapies exist, their recurrence-free survival rates are significantly lower than surgery.Here, author has utilized two antibody-cytokine fusion proteins targeting the tumor specific extradomain B of fibronectin (EDB).These proteins selectively deliver interleukin- 2 (IL2) and tumor necrosis factor (TNF)- alpha to the tumor site.In this brief report, it was present that outcomes of the first six consecutive BCC patients treated in our clin. trial.Bifikafusp alfa (L19IL2) and onfekafusp alfa (L19TNF) are two clin. stage immunocytokines.L19 enables targeted delivery of cytokines to tumor blood vessels, sparing normal tissues and reaching tumor sites undergoing tissue remodelling.A phase 2 study in patients with melanoma indicate that this treatment approach is well-tolerated.In this study, no severe systemic adverse events (AEs) were observedAmong the six patients, five developed flu-like symptoms, such as chills, fever, limb pain, nausea and headache, all classified as CTCAE grade 1-2, with no grade 3 or higher AEs reported.The results described in this report provide a motivation to continue exploring the potential of L19IL2/L19TNF in nonmelanoma skin cancer.